Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Tuesday, May 22, 2018 · 448,164,000 Articles · 3+ Million Readers

MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets’ 2018 Healthcare Conference on Wednesday, February 21, 2018, at 8:30 a.m. ET in New York, NY.  

A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.

/EIN News/ -- About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases.  MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.  MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy – hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).  MyoKardia’s most advanced product candidate is mavacamten (MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial.  MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility.  MyoKardia is currently evaluating MYK-491 in a Phase 1b study in DCM patients.  A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014.  MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.

Contacts

Beth DelGiacco (Investors)
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com

Steven Cooper (Media)
Edelman
415-486-3264
steven.cooper@edelman.com

Primary Logo

Powered by EIN News